STAA Share Price Performance
US$0
-17.40 (-100.00%)
Price US$0
Fair ValueUS$29.67
Share Pricen/a
Narrative Update • Jun 02
STAAR Surgical Company Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
STAA Community Narratives
AN
Fair Value
·Fair Value US$29.67 1.1% overvalued intrinsic discount
Board Opposition And Postponed Vote Will Shape Acquisition Outcome In 2025
2users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
Fair Value
·Fair Value US$16 87.4% overvalued intrinsic discount
Geopolitical Tensions And Regulatory Pressures Will Depress Margins
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$23 30.4% overvalued intrinsic discount
Growing Myopia And Aging Population Will Expand Vision Correction Opportunities
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Board Opposition And Postponed Vote Will Shape Acquisition Outcome In 2025
STAAR Surgical is leaning on a hoped-for pickup in China and a new eye lens launch to turn around slowing demand, while trying to grow faster in other regions. The catch is that its China sales depend heavily on one distributor and shifting inventory, so a recovery could take longer—or look bumpier—than investors expect.Read more
AN
US$29.67
1.1% overvalued intrinsic discount
Fair Value
Profit Margin
9.13%
Future PE
50.57x
Price in 2029
US$36.59
Geopolitical Tensions And Regulatory Pressures Will Depress Margins
STAAR Surgical’s eye lens business faces a tough mix of trade tensions, stricter rules, and rising competition that could squeeze what it earns on each procedure and slow global expansion. At the same time, growing vision problems and new versions of its flagship lens could keep demand strong, making the outlook less straightforward than it looks at first glance.Read more
AN
US$16
87.4% overvalued intrinsic discount
Fair Value
Profit Margin
7.08%
Future PE
38.19x
Price in 2029
US$19.72
Growing Myopia And Aging Population Will Expand Vision Correction Opportunities
Key Takeaways Strong demand drivers and strategic innovation position the company for sustained growth and expanding market share, especially as clinical adoption and patient awareness increase. Manufacturing expansion and targeted market development in Asia-Pacific are expected to drive higher profits, improved margins, and operational efficiency.Read more
AN
US$23
30.4% overvalued intrinsic discount
Fair Value
Profit Margin
13.29%
Future PE
27.3x
Price in 2029
US$28.54
Trending Discussion
Recently Updated Narratives
AN
STAA: China Recovery And Profitability Improvements Will Temper Prior Bearish Reassessment
Fair Value: US$29.67 1.1% overvalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
STAA: Limited China Visibility And Missing Guidance Will Restrain Future Share Performance
Fair Value: US$16 87.4% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
STAA: China Clarity And Post Alcon Reset Will Drive Future Re Rating
Fair Value: US$23 30.4% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
STAAR Surgical Company Key Details
About STAA
- Founded
- 1982
- Employees
- 921
- CEO
- WebsiteView website
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
